Introduction: Giant appendicoliths, which are calcified deposits larger than 2 cm found in the appendix, are uncommon and often linked to appendicitis, as well as complications like perforation or abscess formation. The occurrence of a giant appendicolith leading to peritonitis without accompanying appendicitis is rare, presenting a distinct diagnostic and therapeutic challenge. Presentation of case: A 77-year-old male with beta-thalassemia minor came in with acute pain in the right lower quadrant, along with nausea and vomiting. Upon examination, he showed signs of peritoneal irritation, including rebound tenderness and guarding. Laboratory tests indicated mild leukopenia and normal inflammatory markers. Imaging studies identified a 5 cm appendicolith and localized free fluid suggestive of perforation, along with signs of superimposed peritonitis. Surgical intervention revealed a distended appendix containing the giant appendicolith and an ileocecal perforation, but histopathological analysis showed no evidence of acute appendicitis. The patient underwent an appendectomy and repair of the perforation, resulting in an uneventful recovery. Discussion: Giant appendicoliths can lead to significant mechanical irritation and complications such as perforation, even in the absence of the typical inflammatory response associated with appendicitis. The diagnostic difficulty arises from the lack of fever and elevated inflammatory markers, which are usually present in cases of acute appendicitis. Conclusion: Giant appendicoliths should be included in the differential diagnosis for acute abdominal pain, even when appendicitis is not evident. This case highlights the necessity of thorough approaches for accurate diagnosis and effective treatment. Highlights:
Background: Assisted reproductive technology (ART) is increasingly utilized worldwide, and approximately 30% of ART pregnancies result in twin gestations. Chorionicity strongly influences perinatal risk, yet its specific impact on ART-conceived twins has not been systematically clarified. Objective: To compare obstetrical and neonatal outcomes in assisted ART-conceived monochorionic (MC) versus dichorionic (DC) twin pregnancies and evaluate the impact of chorionicity on maternal and perinatal outcomes. Methods: This systematic review was conducted according to PRISMA guidelines and registered in PROSPERO (CRD42024600292). PubMed, Scopus, and Web of Science were searched through October 2024 for studies comparing obstetrical and neonatal outcomes in ART-conceived monochorionic and dichorionic twin pregnancies. Eligible studies were qualitatively synthesized. Results: Thirty-five studies comprising 15,648 ART-conceived twin pregnancies were included, including 371 monochorionic and 15,277 dichorionic pregnancies. MC pregnancies consistently demonstrated less favorable perinatal outcomes compared with DC pregnancies, including an earlier gestational age at delivery, increased prematurity, lower birth weight, and higher rates of perinatal mortality. By contrast, maternal complications, such as hypertensive disorders, gestational diabetes mellitus, PROM, and cesarean delivery, varied considerably across the studies without a consistent association with chorionicity. The baseline maternal characteristics were generally comparable between the groups. Conclusions: Monochorionicity in ART-conceived twin pregnancies is associated with increased adverse neonatal and perinatal outcomes, particularly prematurity and perinatal mortality, while maternal outcomes appear less clearly influenced by chorionicity. Standardized prospective studies are needed to further clarify the chorionicity-specific risks in ART twin pregnancies.
Dyslipidemia is a major risk factor for cardiovascular disease. Studies have shown that vitamin E has therapeutic effects on lipid metabolism; however, findings remain inconsistent. This meta‐analysis aims to assess the effectiveness of vitamin E administration on the serum lipid panel in patients with dyslipidemia. A database search through January 2026 was conducted to identify relevant randomized controlled trials (RCTs). Relevant data, including triglycerides (TG), total cholesterol (TC), and low‐ and high‐density lipoprotein cholesterol (LDL‐C and HDL‐C), were extracted. The overall effect size was estimated using weighted mean differences (WMDs) with 95% confidence intervals (CIs) via a random‐effects model. The pooled analysis of 22 RCTs (33 intervention arms) demonstrated that vitamin E significantly lowered TG (WMD: −8.14 mg/dL, p = 0.021) and raised HDL‐C (WMD: 1.08 mg/dL, p = 0.037) in patients with dyslipidemia, whereas reductions in TC (WMD: −6.48 mg/dL, p = 0.097) and LDL‐C (WMD: −9.06 mg/dL, p = 0.063) were not significant overall. Exploratory subgroup analyses suggested that tocotrienols may exert greater lipid‐modifying effects than tocopherols, with potentially larger benefits observed at lower doses, among individuals with more pronounced baseline lipid abnormalities, and during shorter intervention periods. In conclusion, vitamin E supplementation in patients with dyslipidemia shows modest improvements in lipid profiles, mainly lowering TG and increasing HDL‐C, with less consistent effects on TC and LDL‐C. Tocotrienols may be more effective than tocopherols, suggesting possible isoform‐specific effects, but overall clinical impact appears limited and requires further confirmation.
23 June 2026 in European Heart Journal - Digital Health
Cardiovascular diseases remain as a leading cause of mortality and morbidity worldwide, with coronary artery disease (CAD) and its complications, collectively referred to as major adverse cardiovascular events (MACEs), necessitating accurate risk stratification. Coronary computed tomography angiography (CCTA) has emerged as a valuable non-invasive imaging modality, and adipose tissue characteristics derived from CCTA have shown promise as imaging biomarkers for MACE prediction. This systematic review and meta-analysis aimed to evaluate the predictive performance of artificial intelligence (AI)-driven models incorporating CCTA-derived adipose tissue radiomic features for forecasting MACEs. A systematic review and random-effects meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies evaluating predictive models developed using different AI algorithms that utilized adipose tissue radiomics as the primary predictor of MACEs in patients undergoing CCTA were included. Model performance was assessed using pooled area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. Eleven studies comprising 47 244 participants were included in the analysis. AI-based models integrating adipose tissue radiomic features with clinical data consistently outperformed conventional risk assessment tools, with pooled AUCs ranging from 82.2% to 87.9%. Among the evaluated approaches, deep learning models demonstrated superior predictive performance compared with traditional machine learning and logistic regression-based models. However, considerable heterogeneity (I² > 96%) was observed across studies, reflecting variations in study design, imaging protocols, and AI methodologies. While AI-enhanced CCTA-based adipose tissue characterization demonstrates considerable potential for improving MACE risk prediction, methodological heterogeneity and limited external validation currently restrict its clinical applicability. Future research should prioritize standardized imaging and analytical methodologies, rigorous clinical and external validation, and transparent reporting to facilitate reliable integration of these AI models into routine cardiovascular risk assessment.
26 July 2026 in Endocrinology, Diabetes & Metabolism
Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is increasingly prevalent and associated with obesity and dyslipidemia, yet effective pharmacological interventions remain limited. Empagliflozin has shown potential benefits in MASLD, although evidence remains limited. This systematic review and meta‐analysis assesses the efficacy of empagliflozin in patients with MASLD, both diabetic and non‐diabetic. Methods: An advanced database search was conducted up to June 1st, 2026, to identify eligible randomized controlled trials (RCTs). The relevant data were extracted from selected studies. Pooled effect sizes were calculated as weighted mean differences (WMDs) with 95% confidence intervals (CIs) using a random‐effects model. Results: Seven RCTs comprising 591 participants were included. Empagliflozin significantly improved liver enzyme profiles. Specifically, it reduced alanine aminotransferase (ALT) (WMD: −12.24 IU/L; p = 0.037), aspartate aminotransferase (AST) (WMD: −9.51 IU/L; p = 0.048), and gamma‐glutamyl transferase (GGT) (WMD: −14.92 IU/L; p = 0.023). Reductions in alkaline phosphatase (ALP) were observed but did not reach statistical significance (WMD: −26.28 IU/L; p = 0.292). Although substantial heterogeneity was observed for several liver enzyme outcomes. Empagliflozin had no significant effect on lipid parameters, including triglycerides (TG), total cholesterol (TC), low‐density and high‐density lipoprotein cholesterols (LDL‐C, HDL‐C). Empagliflozin also produced a statistically significant but modest reduction in body mass index (BMI) (WMD: −0.71 kg/m 2 ; p < 0.001). Empagliflozin also produced a statistically significant but clinically modest reduction in BMI (WMD: −0.71 kg/m 2 ; 95% CI: −1.00 to −0.43; p < 0.001). Conclusion: Empagliflozin appears to improve liver enzymes and modestly reduce BMI in patients with MASLD, while having a neutral effect on lipid parameters. These findings may confer a statistically significant but clinically modest benefit, particularly in patients with coexisting metabolic risk factors. However, the evidence is limited by small sample sizes, short follow‐up periods, and potential publication bias; therefore, the conclusions should be considered preliminary and hypothesis‐generating.